Afatinib irreversibly inhibits EGFR and ErbB2 tyrosine kinases, reducing tumor cell proliferation, invasion, and metastasis, particularly in tumors with EGFR/ErbB2 overexpression or mutations79. The gene discussed is ERBB2; the disease is neoplasm.